CRISPR Therapeutics grants CMO options, RSUs

CRISPR Therapeutics AG granted equity awards to its Chief Medical Officer, Naimish Patel.

Rhea-AI Filing Summary

CRISPR Therapeutics AG granted equity awards to its Chief Medical Officer, Naimish Patel. On March 20, 2026, he received stock options covering 38,499 common shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026.

He was also awarded 30,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on March 20 of 2027, 2028, 2029 and 2030. Both awards are recorded as direct ownership and reflect compensation-related acquisitions rather than open-market purchases.

Insider Trade Summary

Grant/Award: 68,499 shares

Grant/Award 2 txns

Insider Patel Naimish

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	38,499	$0.00	$0.00
Grant/Award	Restricted Stock Units	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 38,499 contracts (Direct); Restricted Stock Units — 30,000 contracts (Direct)

Footnotes (4)

1. F1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
2. F2. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
3. F3. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
4. F4. This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CRSP report for Naimish Patel on this Form 4?

CRISPR Therapeutics reported equity grants to Chief Medical Officer Naimish Patel. He received stock options for 38,499 common shares and 30,000 restricted stock units on March 20, 2026, both recorded as direct, compensation-related acquisitions rather than open-market buying or selling activity.

How many CRISPR Therapeutics stock options were granted to the CMO and at what price?

The CMO received options on 38,499 CRISPR Therapeutics common shares. These options have an exercise price of $46.24 per share and vest in 48 equal monthly installments starting April 20, 2026, providing long-term, performance-aligned equity compensation rather than immediate cash income.

What are the vesting terms of Naimish Patel’s CRSP stock option grant?

The stock option grant vests monthly over four years. All 38,499 underlying common shares vest in 48 equal monthly installments, with the first vesting date on April 20, 2026, creating a gradual vesting schedule that extends through early 2030 for this compensation award.

How many restricted stock units did CRSP grant to its Chief Medical Officer?

CRISPR Therapeutics granted 30,000 restricted stock units to the CMO. Each RSU represents a contingent right to receive one common share, with the award vesting in four equal annual installments from March 20, 2027 through March 20, 2030, aligning compensation with multi-year company performance.

When do the CRISPR Therapeutics RSUs granted to Naimish Patel vest?

The RSUs vest in four annual tranches from 2027 to 2030. One quarter of the 30,000 restricted stock units vests on March 20 in each of 2027, 2028, 2029 and 2030, creating a long-dated equity incentive for the Chief Medical Officer.

Do the Form 4 transactions for CRSP involve open-market share purchases or sales?

No, the reported transactions are equity compensation grants, not market trades. Both the stock option and restricted stock unit awards are coded as acquisitions under transaction code A, reflecting grants by CRISPR Therapeutics rather than open-market buying or selling activity by the insider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 05:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Naimish

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.24	03/20/2026		A(1)		38,499		(2)	03/20/2036	Common Shares	38,499	$0.00	38,499	D
Restricted Stock Units	(3)	03/20/2026		A(1)		30,000		(4)	(4)	Common Shares	30,000	$0.00	30,000	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.

3. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

4. This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)